Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 24, 2026
Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026
Company Deals

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Fineline Cube Mar 24, 2026
Company Deals

Sinomune Pharma Licenses Seysara from Almirall – Exclusive China Rights to Tetracycline Acne Antibiotic

Fineline Cube Mar 24, 2026
Company Deals

Chipscreen Biosciences Licenses Epidaza to Nizhpharm – $29M Deal Expands HDAC Inhibitor into Central Asia and Eastern Europe

Fineline Cube Mar 24, 2026
Policy / Regulatory

NHSA Unveils DRG 3.0 Grouping Scheme Roadmap – Systematic Upgrade Targets 2027 Implementation

Fineline Cube Mar 24, 2026
Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Fineline Cube Mar 24, 2026
Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen

Fineline Cube Mar 24, 2026
Company Drug

Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia

Fineline Cube Mar 21, 2023

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has...

Company

WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials

Fineline Cube Mar 21, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording...

Company Drug

Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review

Fineline Cube Mar 21, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...

Company Drug

Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech

Fineline Cube Mar 21, 2023

German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication...

Company Drug

NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia

Fineline Cube Mar 20, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...

Company Drug

SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China

Fineline Cube Mar 20, 2023

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...

Company Drug

Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns

Fineline Cube Mar 20, 2023

US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...

Company Deals

BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia

Fineline Cube Mar 20, 2023

US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...

Company Deals

Gracell Secures Non-Exclusive License for Cell Therapies from Seagen

Fineline Cube Mar 20, 2023

China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and...

Company Deals

Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development

Fineline Cube Mar 20, 2023

Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised...

Company Drug

Hainan Poly Pharm’s Generic Gadovist Receives FDA Approval for MRI Use

Fineline Cube Mar 20, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received marketing...

Company Drug

Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study

Fineline Cube Mar 20, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...

Company Drug

Hengrui Pharmaceuticals’ Dexmedetomidine Nasal Spray Approved by NMPA

Fineline Cube Mar 20, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing...

Company Deals

Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology

Fineline Cube Mar 20, 2023

Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi...

Company Drug

Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013

Fineline Cube Mar 20, 2023

Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...

Company Drug

Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor

Fineline Cube Mar 20, 2023

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...

Company Deals

Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities

Fineline Cube Mar 20, 2023

China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan...

Company Drug

Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval

Fineline Cube Mar 20, 2023

Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...

Company Medical Device

AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan

Fineline Cube Mar 20, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...

Company Drug

Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine

Fineline Cube Mar 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...

Posts pagination

1 … 522 523 524 … 639

Recent updates

  • Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion
  • Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer
  • Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal
  • Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen
  • Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Others

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.